Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AbD Serotec expands license with MRC
April 2007
SHARING OPTIONS:

MARTINSRIED, GermanyóMorphoSys AG recently announced that its business unit AbD Serotec significantly expanded its license agreement with MRC Technology (MRCT), the technology transfer arm of Great Britain's Medical Research Council (MRC). The agreement, which provides AbD Serotec with access to a broad range of hybridoma cell lines as a source of research antibodies, is extended for a further five years, and includes additional products which will be implemented in AbD Serotec's offering. Financial details of the agreement were not disclosed.
 
The Medical Research Council is a national organization dedicated to improving human health in the UK and abroad.
 
AbD Serotec is the research antibody division of MorphoSys, one of the world's leading antibody technology companies.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.